Ilyang discontinues licensing-out negotiation over ilaprazole

Published: 2011-11-28 06:57:00

Updated: 2011-11-28 06:57:00

Ilyang Pharmaceutical Co. said in a regulatory filing, Thursday, that it has suspended the negotiation of a licensing-out deal with one of multinational drug makers over ilaprazole, a new investigational proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), g...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK